Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 15/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406391 | 0.86 | KLK5 (0.44) | ALOX15TSHRCASP1 | |
| SCHEMBL4408401 | 0.83 | KMT2A (0.42) | CMA1ELANECCR1KMT2A | |
| Trifluoroacetic Acid SCHEMBL2045650 | 0.82 | XIAP (0.49) | ELANECCR1KMT2AALOX15TSHR | |
| SCHEMBL8263228 | 0.82 | ACE (0.55) | CMA1KMT2ACTRC | |
| SCHEMBL4408100 | 0.81 | CMA1 (0.44) | CMA1ELANEKMT2ACTRC | |
| SCHEMBL4409465 | 0.81 | CMA1 (0.49) | CMA1ELANEKMT2ACTRC | |
| SCHEMBL8092675 | 0.79 | L3MBTL1 (0.55) | KMT2AALOX15TSHRCASP1 | |
| SCHEMBL13475726 | 0.79 | PREP (0.57) | ELANEALOX15TSHRCASP1 | |
| SCHEMBL13409456 | 0.79 | PREP (0.57) | ELANEALOX15TSHRCASP1 | |
| SCHEMBL30688534 | 0.74 | CMA1 (0.76) | CMA1ELANEKMT2ACTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1434792-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | Probiodrug AG (DE) | 2004-07-07 | — | — | EP | disclosed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| WO-2003033524-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROBIODRUG AG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | CMA1 889/4885ELANE 1996/4885CCR1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.